Uit het goede hout gesneden

Reacties

1. [verwijderd] 27 april 2011 19:46

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   Heren, hele goede analyse. Zeer aardig die combi TA en FA en aardige hedge gevonden.
   
   Ik moet er nog nader over nadenken. Toch even een voorgedachte die ik vanmorgen kreeg. Ik las over een 20 mld overname van J&J in medische apparaten. Dat is big money.
   
   Helaas een wat minder goede bijgedachte en die was: "kan Philips met medisch wel tegen dergelijk geweld op?"
   
   Ander punt is dat Philips het volgens mij te weinig zoek in apparaatverkoop met full service onderhoud/beheer erbij. Dat is wat langlopende inkomens.
   
   Voor mij als belegger mag de terechte opschoning aan de top bij Philips beginnen bij de veel te weinig dynamische Investorrelations. Lijkt nergens op. De tijd is voorbij van een AV met wat kadotjes voor de aandeelhouder is voldoende
   
   Vanwege afvloeiingregelingen zou dat te veel geld kunnen kosten en daar ben ik als aandeelhouder tegen. Stuur die afdeling dus eerst maar een maand op stage bij bijvoorbeeld Imtech. Zoek een nieuwe IR baas erbij en gooi er wat swing in.
   
   Groet, Jonas
2. [verwijderd] 27 april 2011 21:52

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   
   Even in de rust van Barca. Ergenis en ergenis. Ze passeren tegenwoordig geen mannetje meer en een mooie Krolpass kuinnen of durven ze niet. Knokkers als Neeskens zie je niet. Sommige bedrijvenzoals Philips, Unilever lijken net zo ingezakt: de angst om fouten te maken, belemmert echte actie.
   
   dat heeft echter niets met beleggen te maken en dat laatste schijnt hier wel de bedoeling te zijn. Hier dat J&J- bericht.
   
   " J&J to Buy Synthes for $21.6 Billion
   Published: Wednesday, 27 Apr 2011 | 6:12 AM ET Text Size By: Reuters
   
   Twitter LinkedInMore Share
   Johnson & Johnson is to buy Swiss medical devices maker Synthes for 19 billion Swiss francs ($21.6 billion) in its largest ever buy, boosting its orthopaedic business and reshaping the industry.
   
   
   CNBC.com
   --------------------------------------------------------------------------------
   
   
   The U.S. healthcare group [JNJ 65.47 0.52 (+0.8%) ] will pay 159 Swiss francs in cash and stock for each Synthes share, the two companies said on Wednesday. That was a premium of 8.5 percent over Synthes's closing share price on Tuesday.
   
   A deal had been anticipated after Synthes said on April 18 it was in talks with J&J.
   
   The acquisition, which is likely to close in the first half of 2012, has the backing of both the Synthes and J&J boards and will give J&J a leading position in equipment to treat trauma.
   
   Synthes, which posted sales of $3.7 billion in 2010, makes nails, screws and plates to fix broken bones, as well as artificial spine discs.
   
   "Orthopaedics is a large and growing $37 billion global market and represents an important growth driver for Johnson & Johnson," said Bill Weldon, J&J's chairman and chief executive.
   
   The deal is expected to have a modestly dilutive impact on J&J's adjusted earnings per share for 2012. Crucially, the deal has the backing of Hansjoerg Wyss, who holds 40 percent of Synthes directly and another 8 percent through family trusts, and was seen as key to any deal going through.
   
   Synthes holds its annual general meeting on Thursday.
   
   "It is surprising the deal has been struck between cash and shares. The market consensus, and our view, was it would be all cash, so the quality of the take-out is slightly lower than we anticipated," said Morgan Stanley analyst Michael Jungling.
   
   "The take-out valuation doesn't seem particularly demanding. It's a scarce asset, and the acquisition makes J&J the number one in the world in orthopaedics," Jungling said.
   
   Kepler Capital Markets analyst Florian Gaiser also said he felt the premium was not very high.
   
   "The premium ...reflects the challenges to hand over Synthes to a new owner who needs to fully respect the Synthes culture and the tight relationship to the AO Foundation. These elements will limit the chances of the new owner to influence the business and exploit synergies," he said.
   
   The AO Foundation, which is a key partner to Synthes, has said a deal would not initially result in any change and existing contractual obligations would have to be assumed by the new company.
   
   The AO Foundation is a medically guided non-profit organisation led by an international group of surgeons specialised in the treatment of trauma and disorders of the musculoskeletal system.
   
   Synthes shares were trading 0.41 percent firmer at 147.10 francs, outperforming a 0.2 percent weaker European healthcare index [.SXDP 390.81 0.68 (+0.17%)].
   
   Counter Bid Unlikely
   
   Under the deal, each share of Synthes common stock will be exchanged for 55.65 francs in cash and 103.35 francs in J&J common stock, the groups said.
   
   Synthes and J&J also said the transaction had an estimated net acquisition cost of $19.3 billion as of the close of business on April 26 based on Synthes approximately 119.5 million fully diluted shares outstanding and approximately $2 billion in cash on hand as of signing.
   
   The medical device sector has been consolidating as companies seek economies of scale and new business areas, but analysts doubt anyone will want to take on J&J with a counter-bid for Synthes.
   
   "We do not expect a counter bid as we see J&J as the only logical industrial buyer," Vontobel analyst Carla Baenziger said."
   
   There had previously been speculation J&J, which had cash and short-term investments of $27.7 billion at the end of 2010, was interested in buying British orthopaedics company Smith & Nephew [SN-LN Unavailable ()]. Smith & Nephew shares were trading 3.28 percent lower on the news.
   
   Medical devices and diagnostics accounted for 40 percent of J&J's $61.6 billion in 2010 sales, but the business has been hit by competition and recalls in its hip and knee replacement unit.
   
   J&J owns around 250 separate companies under its corporate umbrella. The group attempted to buy U.S. medical device maker Guidant, which specialised in cardiovascular products, several years ago, but was outbid by Boston Scientific [BSX 7.30 0.03 (+0.41%) ].
   
   Cravath represented Johnson & Johnson in connection with this deal.
   
   Track Stock Funds, Bond Funds, Money Market Funds and ETFs Here
   Copyright 2011 Thomson Reuters. Click for restrictions"
   
   Zo dus 21 mld. Er zijn dagen dat ik dat even niet in mijn achterzak heb. Is zoiets niet te big voor Philips/ Natuurlijk zou het kunnen als de ingezakte machine weer gaat lopen, maar dat wordt een hele heis voor Van der Houten.
   
   Zet er i.v.m. vertrek van Kleisterlee naar Vodafoon, maar een short Vodafoon ook onder. Van Houten zou, denk ik ook niche moeten zoeken en dan doorpakken waar het meer perspectief biedt.
   
   Nu eens kijken of ze nog echt leuk kunnen voetballen.
   
   Groet, Jonas
   
   
3. [verwijderd] 27 april 2011 23:38

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Dank Jonas voor je bijdrage!